DK1131094T3 - Multivalent T.d.Poliovaccine against least diphtheria, poliomyelitis and tetanus - Google Patents

Multivalent T.d.Poliovaccine against least diphtheria, poliomyelitis and tetanus

Info

Publication number
DK1131094T3
DK1131094T3 DK99972544T DK99972544T DK1131094T3 DK 1131094 T3 DK1131094 T3 DK 1131094T3 DK 99972544 T DK99972544 T DK 99972544T DK 99972544 T DK99972544 T DK 99972544T DK 1131094 T3 DK1131094 T3 DK 1131094T3
Authority
DK
Denmark
Prior art keywords
vaccine
diphtheria
poliovaccine
poliomyelitis
tetanus
Prior art date
Application number
DK99972544T
Other languages
Danish (da)
Inventor
Jean Rene Cartier
Patrick Laroche
Original Assignee
Aventis Pasteur Msd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1131094(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur Msd filed Critical Aventis Pasteur Msd
Application granted granted Critical
Publication of DK1131094T3 publication Critical patent/DK1131094T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Vaccine formulated for exclusive use as a repeat ('booster') vaccine in a population already having received a primary vaccine and/or sensitized against at least the poliovirus, Corynebacterium diphteriae and/or C. tetani, is new. Vaccine (I) formulated for exclusive use as a repeat ('booster') vaccine in a population already having received a primary vaccine and/or sensitized against at least the poliovirus, Corynebacterium diphteriae and/or C. tetani, comprises, (1) at least 1.2 mg/ml of aluminum salt; (2) antigens derived from at least the poliovirus; and (3) a quantity of diphtheria anatoxin (DA) used as an antigen of C. diphteriae comprising between 4-16 Flocculation units (Fu);
DK99972544T 1998-11-26 1999-11-25 Multivalent T.d.Poliovaccine against least diphtheria, poliomyelitis and tetanus DK1131094T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98122373A EP1004314A1 (en) 1998-11-26 1998-11-26 T.d. Polio booster vaccine for a primovaccinated or sensibilisated population
EP99972544A EP1131094B1 (en) 1998-11-26 1999-11-25 Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus

Publications (1)

Publication Number Publication Date
DK1131094T3 true DK1131094T3 (en) 2005-02-14

Family

ID=8233032

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99972544T DK1131094T3 (en) 1998-11-26 1999-11-25 Multivalent T.d.Poliovaccine against least diphtheria, poliomyelitis and tetanus

Country Status (14)

Country Link
EP (2) EP1004314A1 (en)
JP (1) JP2003525858A (en)
AT (1) ATE281176T1 (en)
AU (1) AU759221B2 (en)
CA (1) CA2352617A1 (en)
CZ (1) CZ20011860A3 (en)
DE (1) DE69921682T2 (en)
DK (1) DK1131094T3 (en)
ES (1) ES2228175T3 (en)
NZ (1) NZ511933A (en)
PL (1) PL347719A1 (en)
PT (1) PT1131094E (en)
WO (1) WO2000030678A1 (en)
ZA (1) ZA200103634B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
MX2009002561A (en) 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vaccine.
US11179453B2 (en) 2017-07-18 2021-11-23 Serum Institute Of India Pvt Ltd Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
JOP20190242A1 (en) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9710460B8 (en) * 1996-07-02 2021-05-25 Aventis Pasteur multivalent immunogenic composition and vaccine composition
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
EP1028750B1 (en) * 1997-09-15 2006-02-01 Sanofi Pasteur MSD Method for preparing multivalent vaccines
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition

Also Published As

Publication number Publication date
PL347719A1 (en) 2002-04-22
EP1131094A1 (en) 2001-09-12
EP1131094B1 (en) 2004-11-03
NZ511933A (en) 2002-09-27
AU1390100A (en) 2000-06-13
EP1004314A1 (en) 2000-05-31
CA2352617A1 (en) 2000-06-02
ZA200103634B (en) 2002-05-06
AU759221B2 (en) 2003-04-10
CZ20011860A3 (en) 2002-01-16
WO2000030678A1 (en) 2000-06-02
DE69921682T2 (en) 2005-11-03
ATE281176T1 (en) 2004-11-15
DE69921682D1 (en) 2004-12-09
PT1131094E (en) 2005-02-28
ES2228175T3 (en) 2005-04-01
JP2003525858A (en) 2003-09-02

Similar Documents

Publication Publication Date Title
EA200501070A1 (en) POLYVALENT VACCINE COMPOSITION
ES2485940T3 (en) Vaccination combination against Meningitis B / C
NZ513202A (en) Antigen composition comprising Bordetella bronchiseptica, formalin and glutaraldehyde
GB9713156D0 (en) Vaccines
DK0865297T3 (en) Vaccine compositions for intranasal administration comprising chitosan and its use
ES2180651T3 (en) VACCINE CONTAINING NUCLEIC ACIDS.
LU91732I2 (en) Meningococcal menveo-oligosaccharide of group A conjugated to CRM197 protein of Corynebacterium diphtheriae.
DK0654086T3 (en) Vaccines against Aujeszky's disease and other animal diseases containing mutants of pseudo-rabies virus
DK1047784T3 (en) Neissera meningitidis antigens
BR9813930A (en) neisserial antigen
BR9814483A (en) "vaccine"
CY1106206T1 (en) PHARMACEUTICAL COMPOSITION OF FENOFIBRATE COMPLEX AND METHOD OF PREPARATION THEREOF
BR0206293A (en) Immunization Compositions and Methods of Use
DK0988862T3 (en) Formulation containing an antigen, a TH-1 inducing adjuvant and a sparingly water-soluble amino acid for use in immunization
CY1108526T1 (en) CANCER vaccine
ATE244578T1 (en) TREATMENT OF GASTRODUODENAL DISEASE CAUSED BY HELICOBACTER
FR2663130B1 (en) PROJECTION EXPOSURE DEVICE.
DK1131094T3 (en) Multivalent T.d.Poliovaccine against least diphtheria, poliomyelitis and tetanus
DE69738271D1 (en) Rotavirus vaccine
DK0387821T3 (en) 2-Alkyl-4-arylmethylquinolines, their uses and drugs prepared therewith
DK0497121T3 (en) New tetrazole derivatives, processes for their preparation and their use
DK1015026T3 (en) IL-12 as an adjuvant to Bordetella pertussis vaccines
NL300336I2 (en) Mumps vaccine containing a jeryl-lynn virus strain
DE69609739D1 (en) Influenza vaccine containing pertussis toxin
DK0485463T3 (en) Impaired canine parvovirus (CPV), vaccine comprising CPV and method of preventing CPV infection in dogs